Hims & Hers Health, Inc.

HIMS

持有
2026年7月28日Neutral

决策摘要

Hims & Hers Health closed at $29.32 on July 28, 2026, extending its post-FDA panel decline and ending the day below key support at $30. The stock remains in a clear technical downtrend, below the 20-day ($34.01), 50-day ($31.06), and 200-day ($34.09). at 41.7 is bearish and not oversold; histogram continues to deepen at -0.91. Fundamentally, the company faces severe headwinds: FY2026 consensus of -$0.13 (down from -$0.08 30 days ago and from +$0.53 90 days ago) reflects 10 downward revisions in the last month. The balance sheet carries net debt of $381M with a ratio of 254%. The most recent quarter (Q1 2026) was a massive miss (-$0.40 actual vs $0.026 consensus), severely damaging management credibility. Analyst targets average $29.77 (1.6% downside), with a wide range of $21-$40 indicating extreme uncertainty. The FDA advisory panel's narrow 8-6 vote to recommend four peptides for compounding is a long-term positive but was sold as a 'buy the rumor, sell the news' event, with the stock now trading below the pre-panel level. The next high-impact catalyst is Q2 earnings on August 10 (12 days away), where consensus expects -$0.07 . With negative estimate momentum, weak technicals, and binary event risk, the near-term outlook is bearish. Longer-term, a potential peptide revenue stream and DTC platform provide upside optionality, but execution risk and competitive pressure from LLY/NVO remain significant. Investors should view HIMS as a high-risk tactical position, size accordingly, and consider avoiding outright long exposure until fundamentals stabilize or the stock reclaims the 200-day above $34.

投资判断

实时价格

$29.32

推荐分数

40%
40%

置信度

30%
30%

各期限展望

1个月

卖出

短线

6个月

持有

中期

1年

持有

长期

核心催化

The FDA panel recommendation on peptide compounding was the most significant catalyst, but the market's negative reaction suggests that near-term investor focus has shifted back to the company's fundamental challenges, particularly the upcoming Q2 earnings on August 10. The stock's inability to hold gains on the FDA news indicates deep skepticism about the company's ability to execute and monetize the opportunity.

稳定性分类Speculative / Binary组合角色Tactical Trade回撤风险Very High风险画像SpeculativeFDA CatalystTechnical BreakdownNegative EPSHigh DebtEarnings RiskGLP-1 Compounding
决策工作台

价格地图

60日设置

价格轨道

$29.32
止损
当前
$24
$28
$32
$36
止损位

$25.00

买入

$25.00 - $27.00

止盈

$33.00 - $35.00

风险/回报

1.7x

控制仓位

到止损下行

-14.7%

到止盈上行

+19.4%

仓位提示

Speculative only, maximum 1-2% of portfolio. The technical breakdown, negative fundamentals, and upcoming earnings warrant a cautious approach. Consider avoiding any position until the stock stabilizes above $30 on a weekly close or a tradable bottom forms. The high (9.5% of price) demands wide stops and small position sizes. Given the binary risk, sizing should be at the lower end of the range.

投资逻辑快照

什么情况涨

The FDA panel recommendation is a clear positive for the peptide business, potentially opening a new growth avenue worth $2.2B annually. The stock is now deeply oversold on a one-year basis (down 58% from highs) and trades at a discount to DCF intrinsic value ($61.59). If Q2 earnings (Aug 10) show better-than-feared results or if the company provides encouraging guidance on peptide commercialization, the stock could recover significantly. The DTC platform provides a scalable distribution channel for GLP-1s and other therapies. The current price already discounts a significant amount of bad news, providing an attractive entry for patient, risk-tolerant investors with a 6-12 month horizon.

什么情况跌

The company's fundamentals are broken: negative , mounting debt, and a transition to structurally lower-margin branded drugs. The technical breakdown below $30 was a red flag, and the weak bounce suggests further downside to $20 or lower. Even with the FDA panel win, the timeline to profitability is uncertain, and competition from LLY and NVO could erode market share. Insider selling and a departing CAO signal management uncertainty. The Q2 earnings could be another major disappointment, sending the stock below $25. The Zacks Rank of Hold and the predominance of Hold ratings indicate that even the sell-side is not convinced of a near-term turnaround.

A weekly close above $34.09 (the 200-day ) on strong volume would invalidate the bearish thesis, indicating that the FDA positives are outweighing the fundamental concerns and that the stock is likely to trade higher. Conversely, a weekly close below $25.00 would confirm a failed support and open the door to the $20 area, accelerating the downtrend.

  • Q2 2026 earnings on August 10 could be a severe disappointment given the negative estimate revisions trajectory; consensus expects -$0.07 , but a miss of similar magnitude to Q1 could crush the stock, potentially pushing it below $25.
  • The ongoing data-sharing investigation could result in regulatory fines or reputational damage, further pressuring the stock and possibly limiting partnership opportunities.
  • A broad market sell-off ( > 25) would disproportionately impact high-beta names like HIMS (beta 2.34), potentially triggering margin calls on short positions and accelerating downside, regardless of fundamentals.

接下来关注

  • 下一次财报：2026年8月10日
  • The FDA panel recommendation on peptide compounding was the most significant catalyst, but the market's negative reaction suggests that near-term investor focus has shifted back to the company's fundamental challenges, particularly the upcoming Q2 earnings on August 10. The stock's inability to hold gains on the FDA news indicates deep skepticism about the company's ability to execute and monetize the opportunity.
信号仪表盘

决策输入

6 个信号

基本面

1.5%

距分析师均值目标空间

At $29.32, HIMS has a market cap of $6.8B and trades at forward of 22.5x based on FY2027 consensus of $0.62, but FY2026 is negative (-$0.13). The ratio of 2.15x is elevated for a company with negative near-term earnings growth. of 88.5x is extremely expensive given the 3.5% margin. Price-to-sales of 2.86x is moderate for the sector but unsupported by negative operating margins and deteriorating profitability. A DCF analysis from Simply Wall St suggests an intrinsic value of $61.59, implying a 46.8% discount, but this relies on optimistic cash flow growth assumptions that may not materialize given the debt burden and competitive pressures. Overall, the stock appears overvalued on near-term fundamentals but potentially undervalued on a long-term cash flow basis if execution improves, though the wide gap between current price and DCF suggests the market is pricing in significant risk.

技术面

Strongly Bearish

趋势质量

Price at $29.32 is below the 200-day ($34.09), 50-day ($31.06), and 20-day ($34.01), confirming a bearish trend. The / spread is negative and declining, consistent with a death cross already in place. The stock broke below the key $30 support on July 24 and failed to hold a bounce on July 27, closing lower on July 28. The near-term trend is bearish with potential for further downside toward $27 and below.

财报

12天

Decelerating

Q1 2026 (reported May 2026): of -$0.40 missed consensus of $0.026 by 1,664%, driven by restructuring and GLP-1 transition costs. Revenue also missed by 1.86%. The magnitude of the miss severely damaged management credibility.

新闻

Mixed-Bearish

新闻基调

The FDA panel recommendation on peptide compounding was the most significant catalyst, but the market's negative reaction suggests that near-term investor focus has shifted back to the company's fundamental challenges, particularly the upcoming Q2 earnings on August 10. The stock's inability to hold gains on the FDA news indicates deep skepticism about the company's ability to execute and monetize the opportunity.

宏观

Neutral

4.60% 10Y / 18.2 VIX

at 18.2 indicates moderate uncertainty, while the 10-year yield at 4.6% continues to pressure high-growth, high-beta stocks like HIMS (beta 2.34). The broad market is mixed, but HIMS's binary risk profile makes it more sensitive to company-specific events than macro moves. However, a sustained risk-off shift ( >25) could disproportionately exacerbate downside.

稳定性

Speculative / Binary

Tactical Trade

Hims & Hers remains a deeply speculative name given its leveraged balance sheet, negative earnings trajectory, and binary regulatory/competitive outlook. The FDA peptide panel win provides long-term optionality, but near-term fundamentals are deteriorating: FY2026 consensus has fallen to -$0.13, revenue growth slowed to 3.8% YoY, and insider selling persists. The stock's 58% drawdown from the 52-week high reflects pervasive market skepticism. This asset is suitable only as a tactical, event-driven position with strict risk controls; it has no place in a long-term core portfolio. Investors should expect extreme daily swings ( ~9.5% of price) and potential for further downside if Q2 earnings on Aug 10 disappoint.

分析师目标区间

均值目标

$0.00

高低目标

$0 / $0

分析师中值目标

$0.00

共识区间

$21 - $40

— 位分析师
Mean
$21$30$40

市场共识

The mean target of $29.77 implies approximately 1.5% downside from $29.32. The high-low spread is wide ($21-$40), reflecting extreme disagreement about the impact of the FDA panel and the company's ability to execute. Recent actions include target raises from Truist ($27, Hold), Citigroup ($35, Neutral), BofA ($37, Neutral), and Canaccord ($40, Buy), but the consensus remains predominantly Hold (11 of 15 ratings). The lack of strong bullish conviction despite the FDA catalyst suggests analysts are cautious on the fundamental trajectory.

筹码脉冲

内部人信号

Neutral

净偏向

Sell-heavy

内部人持股

0.0%

机构持股

0.0%

解读

The absence of recent discretionary buying combined with prior significant sales by top executives continues to signal a lack of confidence in the company's near-term prospects. The resignation of the CAO adds to governance concerns. Insiders are not using the recent pullback as an opportunity to accumulate shares.

重要活动

No discretionary open-market purchases in the last 20 filings. Three recent transactions are stock awards to directors (Boughton Soleil, Patrick Carroll, Michael Chi) with no cash value. CEO Andrew Dudum sold $3.07M and COO Melissa Baird sold $1.87M between March and May 2026, reducing their holdings meaningfully. The Chief Accounting Officer Irene Becklund resigned effective October 2026.

市场背景

行业

Drug Manufacturers - Specialty & Generic

Mixed-Bearish

情绪

-22

跟踪股票

1

分组

industry

Drug Manufacturers - Specialty & Generic 行业 当前情绪为 Mixed-Bearish，板块平均评分约 40 分，整体偏稳，且leadership is still concentrated。

轮动线索

  • Drug Manufacturers - Specialty & Generic 行业 组内评分变化不大，当前更像是存量博弈。
  • 当前组内偏多评级 0 只，偏空评级 0 只，可见情绪主导方向为 Mixed-Bearish。

重点龙头股

相关龙头股

当前还没有其他已跟踪龙头股。

主题

GLP-1 Compounding Regulation

评分: -20

Mixed-Bearish

The FDA Pharmacy Compounding Advisory Committee meeting concluded on July 24 with a recommendation to ease restrictions on four peptides, which HIMS can compound. This is a regulatory win for the company, but the stock declined sharply, indicating that the market had already discounted a positive outcome and is now focused on the structural challenges of the business. The theme is at an inflection point: while the regulatory path is clearer, the commercial opportunity is uncertain and competition from branded GLP-1 manufacturers (LLY, NVO) remains intense. Capital continues to rotate toward the established leaders rather than niche players.

The FDA panel recommendation was released on July 24, closing a key catalyst window. The market's negative reaction suggests the theme may be fading as a near-term driver, but long-term optionality remains.

  • Institutional flows favor LLY and NVO for regulatory clarity and pricing power, while HIMS remains a high-beta speculative play with execution risk.
  • The massive volume spike and price breakdown on July 24 indicate that short-term speculators are exiting positions post-catalyst, reducing upside pressure.
关键指标
23 项指标

市值

$6.79B

市盈率 (TTM)

0.0

远期市盈率

0.0

营收增速

0.0%

净资产收益率

0.0%

Beta 系数

0.00

完整指标集

另外 17 项指标

估值结构

估值倍数与现金流框架。

市销率

0.0

市净率

0.0

企业价值 / EBITDA

0.0

质量与资产负债表

利润率、杠杆与流动性。

毛利率

0.0%

营业利润率

0.0%

资产负债率

0.0

流动比率

0.00x

速动比率

0.00x

仓位与价格区间

空头仓位与52周区间位置。

流通盘空头占比

0.0%

空头回补天数

0.00x

52周最高

$0.00

52周最低

$0.00

距52周高点

-58.4%

距52周低点

113.4%

公司分类

板块与行业背景。

板块

Healthcare

行业

Drug Manufacturers - Specialty & Generic

其他信号

自由现金流

$0.00

详细分析
估值
At $29.32, HIMS has a market cap of $6.8B and trades at forward of 22.5x based on FY2027 consensus of $0.62, but FY2026 is negative (-$0.13). The ratio of 2.15x is elevated for a company with negative near-term earnings growth. of 88.5x is extremely expensive given the 3.5% margin. Price-to-sales of 2.86x is moderate for the sector but unsupported by negative operating margins and deteriorating profitability. A DCF analysis from Simply Wall St suggests an intrinsic value of $61.59, implying a 46.8% discount, but this relies on optimistic cash flow growth assumptions that may not materialize given the debt burden and competitive pressures. Overall, the stock appears overvalued on near-term fundamentals but potentially undervalued on a long-term cash flow basis if execution improves, though the wide gap between current price and DCF suggests the market is pricing in significant risk.
资产负债表
The balance sheet remains a significant risk. Total debt of $1.13B exceeds cash of $751M, resulting in net debt of $381M. The debt-to-equity ratio of 254% indicates substantial leverage. The current ratio of 1.69 and quick ratio of 1.46 are adequate but provide thin coverage. Operating cash flow of $280M provides some cushion, but free cash flow of $174M is insufficient to meaningfully reduce debt. The cash-to-debt ratio of 0.66 underscores limited financial flexibility. The company is not at immediate risk of default, but leverage limits strategic options and increases vulnerability to a downturn.
增长
Revenue growth has decelerated sharply, with the latest reported quarter showing only 3.8% YoY growth. Consensus expects FY2026 revenue of $2.91B (+23.8% YoY), but this may be optimistic given current trends. The subscriber base grew 9.2% in the latest quarter, but revenue per user declined 5.9% as the mix shifts toward lower-margin branded GLP-1s. is expected to remain negative through FY2026, with a return to profitability in FY2027 ($0.52-$0.62 consensus). The growth profile is under severe pressure from the business model transition, intensifying competition from LLY and NVO, and execution challenges in scaling the peptide business.

生意质量

Gross margins remain high at 72.9%, but the operating margin is -7.9% and margin is only 3.5%. is negative (-2.66%) and is negligible (0.6%), indicating poor capital efficiency. The company lacks a durable competitive advantage in the GLP-1 market; its DTC platform provides some differentiation but does not insulate it from pricing pressure and competition from large pharma. The shift from compounding to branded drugs is structurally dilutive to margins. The business quality is below average and does not support a premium valuation.

资本配置

Management's capital allocation is a concern. The Eucalyptus acquisition added debt, and there are no share buybacks or dividends. Recent insider activity shows only stock awards, no discretionary purchases, and earlier CEO/COO sales signaled lack of confidence. Debt reduction is needed, but cash flow generation is constrained by negative earnings and investment requirements. The company is burning cash to fund operations and growth, which limits financial flexibility.

预期修正

Extremely negative. Over the last 30 days, there were 10 downward revisions for the current quarter and 8 for the next quarter. The FY2026 consensus fell from -$0.08 to -$0.13 in 30 days, a decline of 62.5%. The FY2027 estimate has also been trimmed but remains positive at $0.62. The Zacks Rank is #3 (Hold), but the velocity of downgrades is alarming and suggests near-term earnings expectations continue to deteriorate. The consensus recommendations are predominantly Hold (11 of 15), with only 2 Strong Buys and 1 Strong Sell.

营收增速

—